



To: Office of the Vermont Attorney General

Submitted via email to AGO.highcostprescriptiondrugs@vermont.gov

From: Global Blood Therapeutics, Inc.

Re: New Drug Report Pursuant to 18 V.S.A. § 4637

Global Blood Therapeutics, Inc. (GBT) submits the following information pursuant to 18 V.S.A. § 4637 regarding OXBRYTA™ (voxelotor) tablets, NDC 72786-101-01. OXBRYTA is a prescription medicine indicated for the treatment of sickle cell disease in adults and children 12 years of age and older.

1. Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally.

Vermont law provides that manufacturers may limit the information reported to that which is otherwise in the public domain or publicly available. 18 V.S.A. § 4637(d).

GBT has publicly stated that it will not increase the list price of OXBRYTA for three years and that any future price increases will be tied to inflation. GBT's marketing and pricing plans used in the launch of OXBRYTA are not otherwise in the public domain or publicly available.

2. The estimated volume of patients who may be prescribed the drug.

OXBRYTA is a prescription medicine indicated for the treatment of sickle cell disease in adults and children 12 years of age and older. Although the exact number of people living with sickle cell disease in the United States is unknown, GBT estimates that sickle cell disease affects approximately 107,000 Americans. GBT also estimates that approximately 80% of sickle cell patients are 12 years of age or older, which would represent approximately 86,000 patients. This is only a general approximation based upon these assumptions. It is not an estimate of prescriptions that might be written for OXBRYTA.

3. Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval.

The FDA granted OXBRYTA Breakthrough Therapy designation and Priority Review designation.

4. The date and price of acquisition if the drug was not developed by the manufacturer.

OXBRYTA was developed by GBT.